Objective:

To evaluate a two-marker methylated DNA assay for detecting endometrial cancer using self-collected vaginal fluid samples from patients with abnormal uterine bleeding.

Key Findings:

• The assay achieved 96% sensitivity and 82% specificity for endometrial cancer, but these results cannot be directly translated to clinical rule-out performance.
• Sensitivity varied by histologic subtype, with 93% for grade 1 endometrioid tumors and 100% for grade 2 endometrioid tumors.
• The study's design limits direct translation of results to clinical rule-out performance.

Interpretation:

While the assay shows promise, further validation in a real-world population is necessary to assess its negative predictive value and clinical applicability, particularly for diverse patient demographics.

Limitations:

• The study's case-control design with enriched cancer prevalence affects the generalizability of results.
• Small subgroup sizes for histologic subtypes limit reliable conclusions on subtype-specific performance, impacting overall findings.

Conclusion:

The two-marker methylated DNA assay represents a significant advancement in the detection of endometrial cancer, but further studies are needed before clinical implementation.